OverviewSuggest Edit

Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. The Company's development projects comprise OX382, oral formulation of buprenorphine; OX-CLI, a novel treatment of respiratory disorders, such as asthma and COPD; OX-MPI, for inflammatory related pain; and OX51, a sublingual formulation containing alfentanil for the prevention of acute pain during short surgical and diagnostic procedures.

TypePublic
Founded1995
HQUppsala, SE
Websiteorexo.com

Latest Updates

Employees (est.) (Aug 2020)136(+53%)
Share Price (Aug 2020)KR57.7
Cybersecurity ratingAMore

Key People/Management at Orexo

Robert A. DeLuca

Robert A. DeLuca

President
James Noble

James Noble

Chairman of the Board of Directors
Staffan Lindstrand

Staffan Lindstrand

Director
Joseph DeFeo

Joseph DeFeo

VP Finance
Craig Safran

Craig Safran

VP Commercial Operations
Charlotte Hansson

Charlotte Hansson

Director
Show more

Orexo Office Locations

Orexo has offices in Uppsala and Morristown
Uppsala, SE (HQ)
7E Rapsgatan
Morristown, US
150 Headquarters Plaza
Show all (2)

Orexo Financials and Metrics

Orexo Revenue

Market capitalization (6-Aug-2020)

2.0b

Closing stock price (6-Aug-2020)

57.7
Orexo's current market capitalization is kr2 b.
Show all financial metrics

Orexo Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Orexo Online and Social Media Presence

Embed Graph

Orexo News and Updates

Orexo Interim Report Q2 2020

UPPSALA, Sweden, July 16, 2020 /PRNewswire/ -- Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4), positive EBITDA of SEK 26.5 m (60.4) excluding accelerated DTx US launch Net earnings of SEK -32.5 m...

Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance

UPPSALA, Sweden, July 2, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) announces today the US launch of the scientifically proven digital therapies deprexis® and vorvida®, for treatment of symptoms of depression and management of problematic alcohol misuse respectively....

Orexo Ends Share Buy-back Program

UPPSALA, Sweden, April 6, 2020 /PRNewswire/ -- Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 shares, equivalent to approximately 1.4 per cent of the issued ordinary shares in the company, have been...

Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day

UPPSALA, Sweden, March 17, 2020 /PRNewswire/ -- Orexo AB (publ.), today hosts a Capital Market Day in Stockholm, Sweden. On the day the company will present an overview of the company's growth strategy, pharmaceutical pipeline and digital therapies. In the presentation of the...

Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US

UPPSALA, Sweden, March 6, 2020 /PRNewswire/ -- Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable commercialization in the US. vorvida®, is a digital therapy with clinically proven efficacy for the treatment...

Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17

UPPSALA, Sweden, Feb. 19, 2020 /PRNewswire/ -- Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden, on March 17, at Helio GT30, Grev Turegatan 30. Members of Orexo's management team, including...
Show more

Orexo Frequently Asked Questions

  • When was Orexo founded?

    Orexo was founded in 1995.

  • Who are Orexo key executives?

    Orexo's key executives are Robert A. DeLuca, James Noble and Staffan Lindstrand.

  • How many employees does Orexo have?

    Orexo has 136 employees.

  • Who are Orexo competitors?

    Competitors of Orexo include Sunshine Biopharma, Pharco Pharmaceuticals and Sanfer.

  • Where is Orexo headquarters?

    Orexo headquarters is located at 7E Rapsgatan, Uppsala.

  • Where are Orexo offices?

    Orexo has offices in Uppsala and Morristown.

  • How many offices does Orexo have?

    Orexo has 2 offices.